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Uses of biomarkers in coronary heart disease 
From aetiology to risk modification:  
Simplified steps 
Distal exposure  
 
 
Identify a biomarker 
 
 
Search for a drug-target that affect the biomarker 
 
 
Randomised trial to evaluate effect on outcome 
Structure of the lecture 
Cholesterol and CHD - illustrative example 
 
 
Inflammation [CRP] and CHD 
 
 
Integration of genetics and blood-markers  
for aetiology and drug-target validation 

Distal exposure and biomarker 
Ancel keys Am J Pub health 1957 
Average diet and serum total cholesterol concentration in clinically healthy men  
selected from 21 population groups 
Law M R et al. BMJ 1994;308:367-372 
International studies:  
comparing rates of ischaemic heart disease between 
communities with varying mean cholesterol concentrations 
Biomarkers and clinical event 
Meta-analysis of prospective cohort studies 
Lancet 2005 
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Total cholesterol (mmol/L) 
PSC 
Lancet 2007; 370:1829-39 
IHD mortality (3020 deaths) versus usual non-HDL cholesterol 
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“The cholesterol myth” 
PSC 
Lancet 2007; 370:1829-39 
Identification of a “drug-target”  
(e.g. HMG-CoA reductase) 
Endo A, Kuroda M, Tanzawa K. 
Competitive inhibition of 3-hydroxy-3-methylglutaryl 
coenzyme A reductase by ML-236A and ML-236B fungal 
metabolites, having hypocholesterolemic activity.  
FEBS Lett. 1976 
Drug-target discovery 
The final arbiter of the validity of the  
therapeutic target is the RCT in humans 
Subjects 
Statins 
LDL-C decreased LDL-C unmodified 
CHD 
decreased 
CHD  
unchanged 
Placebo 
Drug Comparator 
Use randomisation to balance confounders 
Validation of a “drug-target”  
(e.g. HMG-CoA reductase) 
RCTs 
Cholesterol Treatment Trialists’ collaborators 
Lancet 2005.  
Drug-target validation 
Cholesterol, HMG-CoA reductase and CHD:  
A successful story 
Dietary cholesterol 
 
 
LDL-cholesterol 
 
 
HMG-CoA reductase inhibitors 
 
 
Randomised trials to evaluate effect on CHD 
Structure of the lecture 
Cholesterol and CHD illustrative example 
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Integration of genetics and blood-markers  
for aetiology and drug-target validation 
Smoking 
 
Blood pressure 
 
Cholesterol 
 
Diabetes 
 
Obesity  
 
Fruit & vegetables 
 
Physical activity  
 
Alcohol consumption 
 
Psychosocial factors 
INTERHEART study: 9 risk factors explain ~90% of CHD 
Smoking 
 
Blood pressure 
 
Cholesterol 
 
Diabetes 
 
Obesity  
 
Fruit & vegetables 
 
Physical activity  
 
Alcohol consumption 
 
Psychosocial factors 
Risk factors with effective known interventions  
that reverse risk of CHD 
Evidence of a role of Inflammation in CHD 
•Experiments in vitro and in vivo in animals 
 
•Associations between infections and CVD 
 
•Associations between inflammatory diseases and CVD 
 
•Associations of CV risk factors and the inflammatory 
 response 
 
•Involvement of inflammatory cells and products in  
atherosclerotic plaques 
 
•Associations between circulating agents/markers of the 
inflammatory response and CVD 
A model linking infection and inflammation with atherosclerosis and 
its acute complications 
Endothelium 
Coagulation 
pathways 
Atherosclerosis 
Local inflammation 
Athero- 
thrombosis 
Infarction 
Local inflammation 
Cytokines 
APRs 
Chronic 
low-grade 
Infection/ 
inflammation 
Systemic  
inflammatory  
response 
Acute infection 
Atherosclerosis timeline 
Genetic predisposition 
Risk factor exposure 
Early lesion Complex lesion 
Clinical events 
Endothelial dysfunction 
Atherosclerosis Atherothrombosis 
Ischaemia 
and  
infarction 
Liver 
Opsonisation 
Complement fixation 
Clearance 
(constant 
half-life 19h) 
Bacterial cell wall 
Fungi, parasites 
Apoptotic cells 
Modified lipids 
Regulators 
IL-1 
IL-6 
TNF-alpha 
Hirschfield and Pepys, JCI 2003 
Biology of C-reactive protein 
Tissue injury 
Infection 
Inflammation 
Adverse non-physiological “stress” 
CRP 
 
phosphocholine 
CRP as a useful biomarker to evaluate the role of  
inflammation on Coronary Heart Disease 
CRP 
Gene 
CRP 
mRNA 
CRP 
Protein 
Endothelial 
dysfunction 
Aherosclero
Thrombosis 
CHD 
CRP was discovered in 1930 
 
 Technology:  ~ mid-1990s Immunoassays methods available 
 
CRP levels were associated with endothelial dysfunction  
 
CRP levels were correlated with higher levels of atherosclerosis (C-IMT) 
 
CRP levels were associated with incident CHD in several prospective studies 
Observation: CRP is associated with risk CHD 
Systematic Review of 31 prospective studies  
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Shah T, et al. Int J Epidemiol 2008  
CRP CHD 
CHD CRP 
CRP CHD 
Smoking, Alcohol, physical inactivity, LDL, excess of adiposity …….…... 
C-reactive protein and  CHD:  
cause, consequence or confounding 
i) CRP plasma & cardiovascular traits
HDL-Cholesterol
ABI baseline
Apolipoprotein-A1
ABI difference-12y
Prothrombin fragment 1+2
ABI difference-5y
Lipoprotein(a)
Homocysteine
Total-Cholesterol
Lp_PLA2
VCAM-1
Factor VII
Fasting glucose
Urinary Fibrinopeptide
Age
Apolipoprotein-B
Systolic BP
Triglycerides
vonWillebrand factor
E-Selectin
Tissue plasminogen activator
Body mass index 
D-dimer
ICAM-1
Fibrinogen
Interleukin-6
Trait
-0.23 (-0.27, -0.19)
-0.22 (-0.28, -0.17)
-0.16 (-0.22, -0.10)
-0.14 (-0.28, 0.00)
-0.02 (-0.10, 0.06)
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ii) CRP-haplotype & cardiovascular traits
C-reactive protein and  CHD: confounding 
Effect of plasma CRP on 26 CV traits 
C-reactive protein and risk of CHD disease 
ERFC Lancet 2009 
Drug intervention 
Randomisation to judge causality 
RCT 
Sample 
Randomisation 
Intervention Control 
Biomarker  
lower 
Biomarker  
Unchanged 
CHD event 
rate lower 
CHD event  
rate higher 
Pepys MB et al.  
Nature 2006; 440: 1217-1221 
Structure of the lecture 
Cholesterol and CHD illustrative example 
 
 
Inflammation [CRP] and CHD 
 
 
Integration of genetics and blood-markers  
for aetiology and drug-target validation 
Can genetics help us to obtain randomised    
- unbiased - evidence about  
environmental factors ? 
Mendel’s second law  
 – the law of independent assortment – 
“the behaviour of each pair of 
differentiating characteristics in hybrid 
union is independent of the other 
differences between the two original 
plants, and, further, the hybrid produces 
just so many kinds of egg and pollen 
cells as there are possible constant 
combination forms” 
 
Gregor Mendel, 1865. 
Mendel in 1862 
• Random allocation of alleles allow us comparing “like with like”   
 
• Genotypes are allocated far in advance of disease process starts  
 
• Genotype are fixed characteristics  
 
• Unidirectional flow of information 
How can we capitalise on the Mendel second law for the 
search of causes ? 
• Mi imise substantially confounding 
 
   Abolish r verse causality 
 
   Minimise / bol sh  regression d lution bias  
Gene mRNA 
Blood 
Protein 
Complex trait  Surrogate 
end-point  
Clinical event 
Random allocation Non-random allocation 
Drug intervention 
Randomisation to judge CRP causality in CHD 
RCT 
Sample 
Randomisation 
Intervention Control 
CRP 
lower 
CRP 
higher 
CV event 
rate lower 
CV event 
rate higher 
Mendelian randomisation 
Population 
Random allocation of alleles 
Genotype aa Genotype AA 
CRP 
lower 
CRP 
higher 
CV event 
rate lower 
CV event 
rate higher 
Genetics 
Drug intervention  
Nature’s Life-time randomised trials  
vs.  
Fixed-duration randomised trials 
 Gamete 
formation 
 Outcome  Middle-age 
~ 5-years 
Randomisation 
Genetics 
 Gamete 
formation 
 Outcome  Middle-age 
Randomisation 
Experiment take 
place 
Mendelian randomisation analysis  
“Instrumental variable” technique  
Intermediate  
Phenotype 
Disease Genotype 
(IP difference/ 5) 
Confounders 
U 
Y X Z 
Assumptions of IV technique for Mendelian randomisation:  
1. The Instrumental variable (IV) Z is associated with exposure of interest X  
2. Z is independent of the confounding factors  U (that confound X-Y association) 
3. Z is independent of outcome Y given X and the confounding factors U  3. Genotype is r lated to the outcome only via its association with the modifiable         
    exposure 
15 SNPs in the CRP gene in individuals of European ancestors  
First step: Adequate selection of the most suitable “tools” to 
conduct a Mendelian randomisation experiment 
CRP
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ii) CRP-haplotype & cardiovascular traits
Maintenance of the random allocation of potential confounders 
among most common CRP haplotypes 
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ii) CRP-haplotype & cardiovascular traits
Maintenance of the random allocation of potential confounders 
among most common CRP haplotypes 
Second step: Get the adequate sample size 
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CRP Coronary Disease Genetics Collaboration  
Mendelian randomisation experiment to assess the 
causal relevance of CRP for coronary disease 
CRP 
CHD G 
Emerging risk factors 
collaboration 
Cross-sectional  
or prospective 
studies 
Case-control or  
Prospective studies 
CRP Coronary Disease Genetic Collaboration (CCGC) 
31 studies, 30,000 cases, 100,000 controls 
 
Coordinators Centres: Cambridge, UCL and LSHTM 
CRP Coronary Disease Genetics Collaboration  
194,418 participants and 46,557 coronary heart disease events 
BMJ 2011 
CRP Coronary Disease Genetics Collaboration  
194,418 participants and 46,557 coronary heart disease events 
Biomarkers and Coronary Heart Disease 
•Excessive number of drug-targets 
(e.g. CVD) 
Causal link? 
Drug targets? 
Inflammation 
C-reactive protein 
SAA 
Interleukins 
Soluble adhesion molecules 
sCD40 ligand 
Haemostasis/ thrombosis 
Fibrinogen 
vWF 
tPA 
D-dimer 
PAI-1 
 
Oxidative stress/lipids 
Homocysteine 
Lipoprotein associated phospholipase A2 
Myeloperoxidase 
 
…….and around 200 others…. 
Output of new molecular entities (NMEs) since 1950 
Munos B. Nature Rev Drug Discovery 2009 
Conclusions 
1. Use of biomarkers in epidemiology provides new option in aetiology – 
drug-developement and risk prediction 
 
2. The sharp increase in technology and the low-cost of these techniques 
will provide access to an increasingly large numbers of biomarkers  
 
3. Old known biases in epidemiology remain as the main challenges to 
translate findings from molecular epidemiology into risk prevention 
 
4. Integration of different layers of biological factors, each of them exposed 
to a different set of biases seems to be a promising approach to 
accelerate the translation of biomarkers research into clinical care 
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